Preliminary results from the ACTIV-1 Immune Modulator clinical trial show that immune modulator drugs, infliximab and abatacept, substantially improved clinical status and reduced deaths in adults hospitalized with COVID-19. The National Institutes of Health (NIH) launched this adaptive Phase 3 clinical trial in October 2020 to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, the randomized, placebo-controlled clinical trial was coordinated and overseen by the NIH’s National Center for Advancing Translational Sciences (NCATS)
NCATS’ Clinical and Translational Science Awards (CTSA) Program and the Trial Innovation Network played a key role in enrolling participants in the United States. More than half of the CTSA Program hubs also contributed their infrastructure and expertise to help advance the clinical trial.
NCATS conducts and supports research on the science and operation of translation — the process by which interventions to improve health are developed and implemented — to allow more treatments to get to more patients more quickly. For more information about how NCATS helps shorten the journey from scientific observation to clinical intervention, visit https://ncats.nih.gov.
The mission of the ISMMS CTSA, ConduITS, is to streamline and centralize the infrastructure needed to accelerate translational research across an ever expanding research enterprise; foster team science responsive to emerging theories, technologies, and data science challenges; innovate processes to increase the quality and efficiency of translational research; develop informatics tools and solutions to accelerate the full translational continuum; and develop innovative educational programs training the workforce needed to respond to the challenges of 21st Century translational science. To learn more about how ConduITS accomplishes its mission please see ConduITS Programs.
ConduITS is supported by NCATS of the NIH’s CTSA Program. Any use of CTSA-supported resources requires citation of grant number UL1TR001433 awarded to ISMMS in the acknowledgment section of every publication resulting from this support. Adherence to the NIH Public Access Policy is also required.